1. A researcher applies a selective D2 receptor (dopamine receptor subtype 2) agonist to cultured pituitary lactotroph cells and measures intracellular signaling and prolactin output. Which of the following sequences of intracellular events most accurately predicts the observed effect on prolactin secretion?
A) D2R activation stimulates adenylyl cyclase through a Gs-coupled mechanism, raising intracellular cyclic AMP (cAMP) and increasing protein kinase A activity, which enhances prolactin gene transcription and increases prolactin secretion.
B) D2R activation opens L-type voltage-gated calcium channels, increasing intracellular calcium and triggering calcium-dependent exocytosis of prolactin-containing secretory granules.
C) D2R activation inhibits adenylyl cyclase through a Gi-coupled mechanism, lowering intracellular cyclic AMP (cAMP), which reduces prolactin gene transcription, synthesis, and secretion.
D) D2R activation stimulates phospholipase C through a Gq-coupled mechanism, increasing inositol trisphosphate (IP3) and diacylglycerol, which promotes prolactin release through protein kinase C activation.
E) D2R activation recruits beta-arrestin and internalizes the receptor without altering cyclic AMP (cAMP), reducing prolactin secretion solely through loss of surface receptor signaling capacity.
ANSWER: C
Rationale:
D2R is a seven-transmembrane, Gi-coupled receptor. Agonist binding activates the inhibitory G protein (Gi), which inhibits adenylyl cyclase and lowers intracellular cyclic AMP (cAMP). Reduced cAMP decreases protein kinase A activity and, in the lactotroph, suppresses prolactin gene transcription, prolactin synthesis, and prolactin secretion. This is the molecular basis for the therapeutic action of dopamine agonists such as cabergoline and bromocriptine in prolactinoma — they recapitulate the tonic dopaminergic inhibition normally delivered to lactotrophs via the hypothalamo-hypophyseal portal circulation.
Option A: Option A is incorrect because D2R is Gi-coupled, not Gs-coupled; it inhibits rather than stimulates adenylyl cyclase, so cAMP falls rather than rises, and prolactin secretion decreases rather than increases.
Option B: Option B is incorrect because D2R activation does not open L-type calcium channels to drive exocytosis; on the contrary, dopaminergic signaling in lactotrophs tends to reduce calcium influx and suppress secretion, the opposite of the calcium-driven exocytosis described.
Option D: Option D is incorrect because D2R is not Gq-coupled and does not signal through phospholipase C, IP3, and protein kinase C to promote prolactin release; that signaling pattern characterizes Gq-coupled receptors such as the TRH receptor, which stimulates rather than inhibits prolactin secretion.
Option E: Option E is incorrect because while beta-arrestin recruitment and receptor internalization can occur with sustained agonist exposure, the primary and immediate mechanism by which D2R agonism reduces prolactin secretion is Gi-mediated inhibition of adenylyl cyclase and reduction of cAMP, not loss of surface receptor signaling capacity.
2. A 29-year-old woman with a microprolactinoma has a history of poor medication adherence and reports she frequently forgets daily doses. She also experienced significant nausea and orthostatic dizziness on a previous dopamine agonist. Based on pharmacokinetic and tolerability considerations, which agent and dosing strategy is most appropriate, and why?
A) Cabergoline dosed twice weekly, because its long elimination half-life (approximately 63 to 68 hours) permits infrequent dosing that supports adherence, and it has substantially better tolerability with lower rates of nausea and orthostatic hypotension than bromocriptine.
B) Bromocriptine dosed three times daily, because its shorter half-life produces more stable steady-state prolactin suppression and its higher dosing frequency reinforces the adherence routine through repetition.
C) Cabergoline dosed daily, because daily administration of cabergoline maintains more constant plasma levels than twice-weekly dosing and minimizes the peak-related nausea that limited the previous agent.
D) Bromocriptine dosed twice daily, because bromocriptine is better tolerated than cabergoline with respect to nausea and orthostatic hypotension and its twice-daily schedule is more convenient than cabergoline's regimen.
E) Either agent at equivalent dosing frequency, because cabergoline and bromocriptine have comparable half-lives and tolerability profiles, so the choice should be based solely on cost.
ANSWER: A
Rationale:
Cabergoline is the preferred first-line dopamine agonist for prolactinoma in most patients, and its pharmacokinetic and tolerability profile makes it especially suitable for this patient. Cabergoline has a long elimination half-life of approximately 63 to 68 hours, which permits twice-weekly oral dosing — a major advantage for a patient with poor adherence to daily regimens. Cabergoline also has significantly better tolerability than bromocriptine, with substantially lower rates of nausea, vomiting, and orthostatic hypotension, which is directly relevant given her prior intolerance. The typical regimen starts at 0.25 mg twice weekly with titration based on prolactin response.
Option B: Option B is incorrect because bromocriptine's shorter half-life (approximately 6 to 8 hours) requires two or three times daily dosing, which worsens rather than supports adherence in a patient who forgets daily doses; bromocriptine also has higher rates of nausea and orthostatic hypotension.
Option C: Option C is incorrect because cabergoline is dosed twice weekly, not daily; daily dosing is unnecessary given its long half-life and would not improve tolerability — the twice-weekly schedule is the adherence advantage.
Option D: Option D is incorrect because bromocriptine is less well tolerated than cabergoline with respect to nausea and orthostatic hypotension, the opposite of the claim; and its twice or three times daily schedule is less convenient than cabergoline's twice-weekly dosing.
Option E: Option E is incorrect because cabergoline and bromocriptine do not have comparable half-lives or tolerability; cabergoline has a markedly longer half-life and superior tolerability, so the choice is not driven solely by cost in a patient with adherence and tolerability concerns.
3. A 50-year-old woman with a macroprolactinoma has been controlled on cabergoline 1 mg per week. Due to a rising prolactin and slight tumor regrowth, her endocrinologist plans to escalate the dose to 3 mg per week. Which of the following is the most appropriate surveillance action related to the principal long-term safety concern of cabergoline at higher doses?
A) Obtain baseline pulmonary function tests and high-resolution chest computed tomography (CT), because the principal long-term risk of higher-dose cabergoline is pleuropulmonary fibrosis, which must be excluded before dose escalation.
B) Obtain a baseline 12-lead electrocardiogram (ECG) to screen for QT prolongation, because cabergoline's principal dose-dependent toxicity is QT-interval prolongation mediated by hERG channel blockade.
C) Obtain baseline liver function tests (LFTs), because the principal dose-limiting toxicity of cabergoline at higher doses is hepatotoxicity requiring monitoring during titration.
D) No additional surveillance is required, because cabergoline valvulopathy occurs only at the very high daily doses used in Parkinson disease and is impossible at any dose used for prolactinoma.
E) Obtain a baseline echocardiogram before escalating the dose, because cabergoline's principal long-term safety concern is cardiac valvulopathy mediated by serotonin 5-HT2B receptor activation on valve fibroblasts; surveillance echocardiography is recommended particularly when doses exceed 2 mg per week or with large cumulative exposure.
ANSWER: E
Rationale:
The principal long-term safety concern with cabergoline is cardiac valvulopathy — fibrotic thickening of cardiac valve leaflets with regurgitation, mediated by cabergoline's agonist activity at serotonin 5-HT2B receptors on cardiac valve interstitial fibroblasts. This is a non-D2R effect unrelated to the therapeutic mechanism. Although the risk at prolactinoma doses is substantially lower than at the high daily doses used in Parkinson disease, guidelines recommend baseline echocardiography before starting or escalating cabergoline, with periodic surveillance, particularly when the weekly dose exceeds 2 mg or cumulative exposure becomes large. Escalating this patient from 1 to 3 mg per week crosses the 2 mg per week threshold, making a baseline echocardiogram the appropriate surveillance step.
Option A: Option A is incorrect because while pleuropulmonary and retroperitoneal fibrosis are rare recognized complications of long-term high-dose ergot dopamine agonist use, they are not the principal long-term safety concern that drives routine surveillance at the doses used for prolactinoma; cardiac valvulopathy and echocardiographic monitoring are the established surveillance focus.
Option B: Option B is incorrect because QT prolongation via hERG channel blockade is a concern for steroidogenesis inhibitors such as ketoconazole and osilodrostat, not the principal dose-dependent toxicity of cabergoline; cabergoline surveillance centers on valvular rather than electrophysiologic monitoring.
Option C: Option C is incorrect because hepatotoxicity is the dose-limiting toxicity of ketoconazole, not cabergoline; cabergoline does not require routine LFT monitoring as its principal safety surveillance.
Option D: Option D is incorrect because although valvulopathy risk is much lower at prolactinoma doses than at Parkinson disease doses, it is not impossible, and guidelines specifically recommend echocardiographic surveillance above 2 mg per week; dismissing surveillance entirely contradicts the recommendation to obtain a baseline echocardiogram before crossing that threshold.
4. A 40-year-old man presents with a 3 cm sellar mass causing visual field deficits. His serum prolactin is reported as 38 ng/mL (upper limit of normal approximately 20 ng/mL). The clinical team is deciding between transsphenoidal surgery for a presumed non-functioning adenoma and a trial of dopamine agonist therapy. Which of the following is the most appropriate next step to resolve this diagnostic ambiguity?
A) Proceed to transsphenoidal surgery, because a prolactin level only mildly above normal in the presence of a large mass establishes a non-functioning adenoma with stalk-effect hyperprolactinemia, which will not respond to dopamine agonists.
B) Request a 1:100 serial dilution of the serum prolactin sample to evaluate for the hook effect, because a very large prolactinoma can produce extremely high prolactin concentrations that saturate the immunometric assay and yield a falsely low measured value; if the diluted value rises substantially, the lesion is a macroprolactinoma treatable with a dopamine agonist.
C) Initiate empiric high-dose cabergoline without further laboratory testing, because any large pituitary mass should receive a dopamine agonist trial regardless of the measured prolactin level.
D) Order a serum macroprolactin (big-big prolactin) assay, because the mild prolactin elevation in a large mass indicates macroprolactinemia, which is the most likely explanation for the discordance and requires no treatment.
E) Repeat the prolactin measurement on three separate days to average out pulsatile variation, because pulsatile prolactin secretion is the most likely cause of an artifactually low single value in a patient with a large pituitary mass.
ANSWER: B
Rationale:
A large sellar mass accompanied by only a mildly elevated prolactin is a classic setup for the hook effect. In very large macroprolactinomas, extremely high prolactin concentrations saturate both the capture and detection antibodies of two-site immunometric assays, preventing proper sandwich formation and producing a falsely low or normal measured value. The appropriate next step is to request a serial dilution of the serum (typically 1:100); if the true prolactin is very high, the diluted measurement rises substantially, confirming a macroprolactinoma. This distinction is critical because a macroprolactinoma is treated medically with a dopamine agonist, often avoiding surgery, whereas misclassifying it as a non-functioning adenoma could lead to unnecessary operation.
Option A: Option A is incorrect because proceeding to surgery without excluding the hook effect risks operating on a macroprolactinoma that would respond to cabergoline with both prolactin normalization and tumor shrinkage; the mild measured prolactin does not reliably establish a non-functioning adenoma in this setting.
Option C: Option C is incorrect because initiating empiric cabergoline without confirming the diagnosis is inappropriate; while the hook effect is likely, the diagnosis should be confirmed by serial dilution before committing to therapy, and not every large pituitary mass is a prolactinoma.
Option D: Option D is incorrect because macroprolactinemia (big-big prolactin, typically IgG-bound) is associated with an elevated measured prolactin that overestimates bioactive prolactin — it does not explain a falsely low value in the presence of a large mass, which is the opposite scenario from the hook effect.
Option E: Option E is incorrect because pulsatile prolactin variation does not produce the marked artifactual underestimation seen with the hook effect; repeating the measurement without dilution would not unmask an assay-saturating high prolactin concentration.
5. A 36-year-old woman with an invasive macroprolactinoma has failed to normalize prolactin or achieve meaningful tumor shrinkage after 18 months on the maximally tolerated dose of cabergoline. She is classified as having dopamine agonist-resistant disease. Which of the following best describes the appropriate next management consideration for true cabergoline resistance?
A) Switch to bromocriptine, because bromocriptine reliably overcomes cabergoline resistance through its higher D2 receptor (D2R) affinity and will normalize prolactin in most cabergoline-resistant tumors.
B) Add a somatostatin analog such as octreotide, because somatostatin receptor activation provides a complementary prolactin-lowering pathway that restores control in cabergoline-resistant prolactinomas.
C) Continue cabergoline at the same dose indefinitely, because resistance is usually transient and most patients achieve normalization if the same dose is maintained for an additional 2 to 3 years.
D) Pursue transsphenoidal surgery, and for aggressive or refractory tumors consider temozolomide, because true cabergoline resistance — driven by reduced D2R expression in the tumor — typically necessitates surgical management, with temozolomide reserved for aggressive or malignant pituitary tumors that fail surgery.
E) Initiate pasireotide, because the pan-somatostatin receptor agonism of pasireotide is specifically indicated for dopamine agonist-resistant prolactinomas and is the established standard of care in this setting.
ANSWER: D
Rationale:
True dopamine agonist resistance — failure to normalize prolactin or achieve at least 50% tumor volume reduction at maximally tolerated doses — occurs in approximately 10 to 15% of cabergoline-treated patients and is more common with larger, more invasive tumors and those with reduced D2R protein expression. Partial resistance may respond to dose escalation within the tolerated range, but for complete resistance the appropriate management is transsphenoidal surgery to achieve secretory control and decompression. For aggressive or malignant pituitary tumors that fail surgery, temozolomide (an alkylating agent) is the established next-line systemic option.
Option A: Option A is incorrect because bromocriptine has a lower D2R affinity than cabergoline and does not reliably overcome cabergoline resistance; cabergoline is the more potent and better-tolerated agent, and switching to bromocriptine is not an effective strategy for true cabergoline-resistant disease.
Option B: Option B is incorrect because octreotide and other somatostatin analogs are not effective therapy for prolactinoma; lactotroph adenomas are driven by dopaminergic, not somatostatinergic, regulation, and somatostatin analogs do not restore control in cabergoline-resistant prolactinomas.
Option C: Option C is incorrect because continuing the same dose indefinitely does not overcome true resistance; resistance in this context reflects reduced D2R expression rather than a transient state that resolves with prolonged identical dosing.
Option E: Option E is incorrect because pasireotide is indicated for Cushing disease and acromegaly, not for dopamine agonist-resistant prolactinoma; prolactinomas are not effectively treated with somatostatin receptor agonists, and pasireotide is not the standard of care in this setting.
6. A 43-year-old woman with persistent Cushing disease is started on pasireotide after a prior trial of octreotide produced no meaningful reduction in cortisol. Which of the following best explains why pasireotide is effective in Cushing disease whereas first-generation somatostatin analogs such as octreotide are not?
A) Corticotroph adenomas predominantly express somatostatin receptor subtype 5 (SSTR5) rather than SSTR2; pasireotide has high SSTR5 affinity and therefore suppresses adrenocorticotropic hormone (ACTH) secretion from the corticotroph, whereas octreotide acts mainly through SSTR2, which corticotroph adenomas express at low density.
B) Pasireotide is a glucocorticoid receptor (GR) antagonist that blocks cortisol signaling at peripheral tissues, while octreotide has no GR activity; the receptor-blocking mechanism is what makes pasireotide effective where octreotide fails.
C) Pasireotide inhibits adrenal CYP11B1 (11-beta-hydroxylase) directly, lowering cortisol synthesis, whereas octreotide has no adrenal enzyme-inhibiting activity; this adrenal action explains the efficacy difference.
D) Octreotide and pasireotide both act on SSTR2, but pasireotide reaches higher plasma concentrations, allowing it to saturate SSTR2 on corticotroph adenoma cells more completely and produce greater ACTH suppression.
E) Pasireotide activates dopamine D2 receptors (D2R) on corticotroph adenoma cells in addition to its somatostatin activity, and this dopaminergic action accounts for its superiority over octreotide in Cushing disease.
ANSWER: A
Rationale:
Corticotroph adenomas that cause Cushing disease predominantly express somatostatin receptor subtype 5 (SSTR5), with relatively low SSTR2 density. First-generation somatostatin analogs such as octreotide and lanreotide act mainly through SSTR2, which explains their limited efficacy in Cushing disease. Pasireotide is a pan-somatostatin receptor agonist with particularly high affinity for SSTR5; by activating the SSTR5 receptors predominantly expressed on corticotroph adenoma cells, pasireotide suppresses ACTH secretion and thereby reduces downstream adrenal cortisol production. This receptor-subtype mismatch — SSTR5-rich tumors versus an SSTR2-targeted drug — is precisely why octreotide fails and pasireotide succeeds.
Option B: Option B is incorrect because pasireotide is a somatostatin receptor agonist, not a glucocorticoid receptor antagonist; mifepristone is the GR antagonist used in Cushing syndrome, and pasireotide's mechanism is suppression of ACTH at the pituitary, not blockade of cortisol at peripheral tissues.
Option C: Option C is incorrect because pasireotide does not directly inhibit adrenal CYP11B1; adrenal steroidogenesis inhibition is the mechanism of ketoconazole, metyrapone, and osilodrostat, whereas pasireotide acts at the pituitary corticotroph through SSTR5.
Option D: Option D is incorrect because the efficacy difference is not explained by higher pasireotide concentrations saturating SSTR2; it is explained by pasireotide's affinity for SSTR5, the receptor subtype that corticotroph adenomas actually express in abundance, whereas octreotide targets the sparsely expressed SSTR2.
Option E: Option E is incorrect because pasireotide does not activate dopamine D2 receptors; its mechanism is somatostatin receptor agonism (notably SSTR5), and the dopaminergic action of cabergoline is a separate pharmacological pathway, not a property of pasireotide.
7. A 47-year-old man with Cushing disease is about to begin pasireotide. He has no prior diagnosis of diabetes, but his clinician anticipates a high likelihood of treatment-emergent hyperglycemia and wishes to plan management in advance. Which of the following is the most appropriate anticipatory plan and its pharmacological rationale?
A) Plan to start a sulfonylurea at the first sign of hyperglycemia, because pasireotide-induced hyperglycemia results purely from insulin resistance and sulfonylureas overcome it by forcing insulin release regardless of somatostatin receptor activation.
B) Plan no specific monitoring, because pasireotide-induced hyperglycemia occurs in fewer than 10% of patients and resolves spontaneously without pharmacological intervention.
C) Counsel the patient about the high likelihood of hyperglycemia, monitor glucose and HbA1c, and plan to use a glucagon-like peptide-1 (GLP-1) receptor agonist as the preferred first-line agent if hyperglycemia develops, because pasireotide suppresses insulin secretion through somatostatin receptor activation on pancreatic islet cells, and GLP-1 receptor agonists restore insulin secretion and suppress glucagon through a pathway not blocked by somatostatin receptors.
D) Plan to discontinue pasireotide immediately if fasting glucose rises above normal, because any treatment-emergent hyperglycemia indicates that pasireotide cannot be safely continued and an alternative drug class must replace it.
E) Plan to start a thiazolidinedione such as pioglitazone preemptively, because pasireotide-induced hyperglycemia is driven primarily by peripheral insulin resistance from residual cortisol excess, which insulin sensitizers directly reverse.
ANSWER: C
Rationale:
Pasireotide-induced hyperglycemia is common, occurring in a majority of Cushing disease patients (often more than 70%), and results from somatostatin receptor-mediated suppression of pancreatic insulin secretion together with impaired incretin and glucagon regulation. Because the defect is principally one of impaired insulin secretion rather than pure insulin resistance, the preferred anticipatory plan is to counsel the patient, monitor glucose and HbA1c, and use a GLP-1 receptor agonist as first-line therapy if hyperglycemia develops. GLP-1 receptor agonists stimulate insulin secretion and suppress glucagon through GLP-1 receptor signaling that is not antagonized by somatostatin receptor activation, so they retain efficacy in the presence of pasireotide and directly counter the underlying mechanism.
Option A: Option A is incorrect because pasireotide-induced hyperglycemia is driven by suppressed insulin secretion rather than pure insulin resistance, and sulfonylurea-stimulated insulin release is partially blunted by concurrent somatostatin receptor activation, making sulfonylureas less effective than GLP-1 receptor agonists in this setting.
Option B: Option B is incorrect because pasireotide-induced hyperglycemia is common (well over 50% of patients), not rare, and frequently requires active pharmacological management rather than resolving spontaneously.
Option D: Option D is incorrect because treatment-emergent hyperglycemia does not mandate immediate discontinuation of pasireotide; when the drug is providing meaningful cortisol control, hyperglycemia is managed pharmacologically with preferred agents rather than by abandoning effective therapy.
Option E: Option E is incorrect because the primary driver of pasireotide-induced hyperglycemia is impaired insulin secretion, not peripheral insulin resistance; thiazolidinediones address insulin resistance and do not restore the suppressed insulin secretion that characterizes this drug effect, so they are not the preferred first-line agents.
8. A 55-year-old woman with Cushing disease taking simvastatin for hyperlipidemia is started on ketoconazole for cortisol control. Which of the following best predicts the most clinically significant drug interaction and its mechanism?
A) Ketoconazole will induce CYP3A4, lowering simvastatin concentrations and reducing its lipid-lowering efficacy, so the simvastatin dose will need to be increased to maintain cholesterol control.
B) Ketoconazole will displace simvastatin from plasma protein binding sites, transiently increasing free simvastatin without a clinically meaningful change in total drug exposure.
C) Ketoconazole and simvastatin have no clinically significant interaction, because simvastatin is eliminated unchanged by the kidney and is not dependent on hepatic cytochrome P450 metabolism.
D) Ketoconazole will inhibit the organic anion transporting polypeptide (OATP) hepatic uptake transporter, decreasing simvastatin delivery to the liver and thereby reducing both its efficacy and its myopathy risk.
E) Ketoconazole will strongly inhibit CYP3A4, markedly increasing simvastatin plasma concentrations and raising the risk of statin-associated myopathy and rhabdomyolysis, because simvastatin is a CYP3A4 substrate.
ANSWER: E
Rationale:
Ketoconazole is a strong inhibitor of CYP3A4, and simvastatin is a CYP3A4 substrate whose systemic exposure rises substantially when CYP3A4 is inhibited. Co-administration markedly increases simvastatin plasma concentrations, raising the risk of statin-associated myopathy and rhabdomyolysis. This is one of the clinically important interactions driven by ketoconazole's potent CYP3A4 inhibition, which also affects cyclosporine, tacrolimus, calcium channel blockers, midazolam, and many other CYP3A4 substrates. The appropriate clinical response is to avoid the combination, reduce the statin dose substantially, or switch to a statin less dependent on CYP3A4 metabolism.
Option A: Option A is incorrect because ketoconazole inhibits rather than induces CYP3A4; inhibition raises simvastatin concentrations rather than lowering them, so the statin dose would need to be reduced, not increased.
Option B: Option B is incorrect because the dominant mechanism of this interaction is CYP3A4 metabolic inhibition, not plasma protein displacement; protein displacement does not account for the large, clinically significant increase in simvastatin exposure that drives myopathy risk.
Option C: Option C is incorrect because simvastatin is extensively metabolized by hepatic CYP3A4 and is not eliminated unchanged by the kidney; there is a major, well-established interaction between ketoconazole and simvastatin.
Option D: Option D is incorrect because the clinically significant interaction is CYP3A4 inhibition increasing simvastatin exposure; while OATP transporters do participate in statin hepatic uptake, ketoconazole's effect on simvastatin is driven by metabolic inhibition that increases — not decreases — systemic exposure and myopathy risk.
9. A 49-year-old man is started on ketoconazole for Cushing disease. Which of the following best describes the principal organ-specific toxicity requiring systematic monitoring and the appropriate surveillance approach during therapy?
A) Nephrotoxicity is the principal concern; serum creatinine and electrolytes should be checked weekly, because ketoconazole causes acute tubular necrosis through direct renal cytochrome inhibition.
B) Hepatotoxicity is the principal concern; liver function tests (LFTs) should be monitored every 2 to 4 weeks during initiation and monthly thereafter, because ketoconazole causes elevated liver enzymes in up to 20% of patients and severe hepatotoxicity in a smaller subset, requiring discontinuation if significant enzyme elevation or clinical hepatotoxicity develops.
C) Bone marrow suppression is the principal concern; a complete blood count (CBC) should be checked every 2 weeks, because ketoconazole frequently causes agranulocytosis early in therapy.
D) Pulmonary fibrosis is the principal concern; pulmonary function tests should be performed quarterly, because ketoconazole is an ergot-derived agent associated with fibrotic lung disease.
E) Thyroid dysfunction is the principal concern; thyroid-stimulating hormone (TSH) should be monitored every 6 weeks, because ketoconazole's primary toxicity is inhibition of thyroid hormone synthesis.
ANSWER: B
Rationale:
Hepatotoxicity is the principal organ-specific toxicity of ketoconazole and the basis for its restricted use in several markets. Ketoconazole causes elevated liver enzymes in up to roughly 20% of patients, with severe hepatotoxicity in a smaller subset (on the order of a few percent). The appropriate surveillance is LFT monitoring every 2 to 4 weeks during initiation and monthly thereafter, with discontinuation if significant transaminase elevation or clinical signs of hepatotoxicity develop. This monitoring requirement is a defining practical feature of ketoconazole therapy in Cushing disease.
Option A: Option A is incorrect because nephrotoxicity from acute tubular necrosis is not the principal toxicity of ketoconazole; the drug's defining organ toxicity is hepatic, and routine weekly creatinine monitoring is not the established surveillance approach.
Option C: Option C is incorrect because agranulocytosis and routine biweekly CBC monitoring are not characteristic of ketoconazole; bone marrow suppression is not its principal toxicity.
Option D: Option D is incorrect because pulmonary fibrosis is associated with long-term high-dose ergot dopamine agonists, not with ketoconazole, which is an imidazole antifungal rather than an ergot derivative.
Option E: Option E is incorrect because while ketoconazole can affect steroidogenic enzymes broadly, its principal monitored toxicity is hepatotoxicity, not thyroid hormone synthesis inhibition, and routine TSH surveillance is not the defining monitoring requirement of ketoconazole therapy.
10. A 41-year-old woman with Cushing disease is started on metyrapone, and her clinician orders serial plasma 11-deoxycortisol levels. Two weeks into therapy, the 11-deoxycortisol level has risen substantially while urinary free cortisol (UFC) has begun to fall. Which of the following is the correct interpretation of this laboratory pattern?
A) The rising 11-deoxycortisol indicates metyrapone treatment failure, because accumulation of this precursor signals that the drug is not blocking cortisol synthesis effectively and the dose should be reduced.
B) The rising 11-deoxycortisol indicates that metyrapone is inhibiting CYP11A1 (cholesterol side-chain cleavage enzyme), causing the entire steroidogenic pathway to back up at its first step.
C) The rising 11-deoxycortisol reflects metyrapone-induced adrenal insufficiency, because the precursor accumulates only when cortisol output has dropped to dangerously low levels requiring immediate glucocorticoid replacement.
D) The rising 11-deoxycortisol confirms the expected pharmacodynamic effect of metyrapone: by inhibiting CYP11B1 (11-beta-hydroxylase), metyrapone blocks the conversion of 11-deoxycortisol to cortisol, so the upstream precursor 11-deoxycortisol accumulates while cortisol falls, and this rise serves as a surrogate marker of adequate enzyme blockade.
E) The rising 11-deoxycortisol indicates conversion of metyrapone to an active metabolite that stimulates adrenal androgen synthesis, and androgen-related adverse effects should be anticipated as the primary clinical consequence.
ANSWER: D
Rationale:
Metyrapone selectively inhibits CYP11B1 (11-beta-hydroxylase), the enzyme that catalyzes the final step in cortisol synthesis — conversion of 11-deoxycortisol to cortisol. When this step is blocked, the immediate upstream substrate 11-deoxycortisol accumulates in plasma while cortisol output falls. A rising 11-deoxycortisol is therefore the expected pharmacodynamic signature of effective CYP11B1 inhibition and serves as a surrogate marker confirming the drug is acting on its target; the concurrent fall in UFC confirms the intended cortisol-lowering effect. This is exactly the laboratory pattern that indicates metyrapone is working as designed.
Option A: Option A is incorrect because rising 11-deoxycortisol indicates effective enzyme blockade, not treatment failure; the precursor accumulates precisely because the drug is preventing its conversion to cortisol, so the dose should not be reduced on this basis.
Option B: Option B is incorrect because metyrapone does not inhibit CYP11A1 (the cholesterol side-chain cleavage enzyme); its selective target is CYP11B1, and the 11-deoxycortisol accumulation is specific to a block at the terminal hydroxylation step, not a backup at the first step of steroidogenesis.
Option C: Option C is incorrect because rising 11-deoxycortisol is a direct marker of enzyme inhibition, not a marker of adrenal insufficiency; while excessive metyrapone can cause adrenal insufficiency, the precursor rise itself simply reflects target engagement and does not by itself signal dangerously low cortisol requiring immediate replacement.
Option E: Option E is incorrect because the 11-deoxycortisol that accumulates above the CYP11B1 block is not androgenic, and metyrapone does not significantly stimulate adrenal androgen synthesis; the precursor rise reflects enzyme blockade rather than conversion to an androgen-stimulating metabolite.
11. A 53-year-old woman on metyrapone for Cushing disease develops new-onset hypertension and a serum potassium of 3.1 mEq/L after several weeks of therapy, even as her urinary free cortisol (UFC) falls appropriately. Which of the following best explains the mechanism of these findings?
A) Metyrapone's block of CYP11B1 (11-beta-hydroxylase) prevents conversion of 11-deoxycorticosterone (DOC) to corticosterone, so DOC accumulates; DOC is a weak mineralocorticoid that activates renal mineralocorticoid receptors, promoting sodium retention and potassium excretion, producing hypertension and hypokalemia.
B) Metyrapone directly inhibits the renal sodium-potassium ATPase, causing sodium retention and potassium loss independent of any steroid precursor accumulation.
C) Metyrapone causes hypertension and hypokalemia by inducing renin release through CYP11B2 (aldosterone synthase) inhibition, which drives secondary hyperaldosteronism and mineralocorticoid excess.
D) The hypertension and hypokalemia reflect cortisol withdrawal, as falling cortisol removes its normal vasodilatory effect and unmasks latent essential hypertension while shifting potassium intracellularly.
E) Metyrapone activates the glucocorticoid receptor in vascular smooth muscle as an off-target agonist effect, producing cortisol-like vasoconstriction and renal potassium wasting.
ANSWER: A
Rationale:
Metyrapone's inhibition of CYP11B1 (11-beta-hydroxylase) blocks not only the conversion of 11-deoxycortisol to cortisol but also the conversion of 11-deoxycorticosterone (DOC) to corticosterone in the mineralocorticoid pathway. Because the block is proximal to CYP11B2 (aldosterone synthase), DOC accumulates, driven further by the rise in ACTH that accompanies falling cortisol. DOC is a weak mineralocorticoid; in excess it activates renal mineralocorticoid receptors in the collecting duct, promoting sodium and water retention and increasing potassium excretion. The clinical result is hypertension and hypokalemia, which can emerge even as the drug effectively lowers cortisol (falling UFC).
Option B: Option B is incorrect because metyrapone does not directly inhibit the renal sodium-potassium ATPase; the electrolyte and blood pressure effects are mediated by DOC accumulation acting on mineralocorticoid receptors, not by a direct renal pump effect.
Option C: Option C is incorrect because metyrapone's primary target is CYP11B1, not CYP11B2; the mechanism is DOC-driven mineralocorticoid excess, not renin-driven secondary hyperaldosteronism, and selective CYP11B2 inhibition is a property of osilodrostat rather than metyrapone.
Option D: Option D is incorrect because the hypertension and hypokalemia are caused by DOC-mediated mineralocorticoid excess, not by cortisol withdrawal unmasking essential hypertension; cortisol withdrawal would not produce the specific combination of hypertension with renal potassium wasting seen here.
Option E: Option E is incorrect because metyrapone does not act as a glucocorticoid receptor agonist in vascular smooth muscle; the mineralocorticoid-excess physiology is explained by DOC accumulation activating mineralocorticoid receptors, not by off-target glucocorticoid receptor agonism.
12. A 46-year-old man with Cushing disease was previously on metyrapone (where he developed hypertension and hypokalemia) and is now switched to osilodrostat. After dose titration, he develops hypokalemia again, but this time accompanied by hypotension rather than hypertension. Which of the following best explains the different electrolyte and blood pressure pattern between the two drugs?
A) Osilodrostat, like metyrapone, causes 11-deoxycorticosterone (DOC) accumulation, so the hypotension is unrelated to its mechanism and must reflect intercurrent dehydration rather than a drug effect.
B) Osilodrostat produces hypotension because it inhibits CYP3A4 and thereby increases the plasma concentration of the patient's antihypertensive medications, an interaction unrelated to adrenal steroidogenesis.
C) Unlike metyrapone, osilodrostat also inhibits CYP11B2 (aldosterone synthase), reducing aldosterone synthesis; the resulting aldosterone deficiency causes hypotension and hypokalemia, in contrast to the DOC-driven mineralocorticoid excess (hypertension and hypokalemia) seen with metyrapone.
D) Osilodrostat causes hypotension and hypokalemia by inhibiting CYP17A1 (17-alpha-hydroxylase), which depletes both cortisol and androgens and secondarily reduces blood pressure through androgen deficiency.
E) Osilodrostat produces hypotension because it is a direct arterial vasodilator at therapeutic concentrations, and the hypokalemia is a reflex consequence of compensatory aldosterone release.
ANSWER: C
Rationale:
Osilodrostat is a potent CYP11B1 (11-beta-hydroxylase) inhibitor that additionally inhibits CYP11B2 (aldosterone synthase). This dual inhibition distinguishes it from metyrapone, which selectively inhibits CYP11B1. With metyrapone, the proximal CYP11B1 block causes DOC to accumulate, producing mineralocorticoid excess (hypertension and hypokalemia). With osilodrostat, the additional CYP11B2 inhibition reduces aldosterone synthesis, so rather than mineralocorticoid excess, the patient can develop aldosterone deficiency — producing hypotension and hypokalemia. The hypokalemia in both cases relates to mineralocorticoid pathway perturbation, but the blood pressure direction differs because of the contrasting mineralocorticoid status. This is why electrolyte and blood pressure monitoring is required at each osilodrostat dose titration.
Option A: Option A is incorrect because osilodrostat does not produce the DOC accumulation pattern of metyrapone; its CYP11B2 inhibition reduces aldosterone, and the hypotension is a direct consequence of its mechanism rather than incidental dehydration.
Option B: Option B is incorrect because osilodrostat is a CYP2D6 inhibitor and a CYP3A4 substrate, not a CYP3A4 inhibitor that raises antihypertensive levels; the hypotension is explained by aldosterone deficiency from CYP11B2 inhibition, not by a CYP3A4-mediated drug interaction.
Option D: Option D is incorrect because osilodrostat's distinguishing action is CYP11B2 inhibition, not CYP17A1 inhibition; CYP17A1 is the principal target of ketoconazole, and androgen deficiency is not the mechanism of osilodrostat-associated hypotension.
Option E: Option E is incorrect because osilodrostat is not a direct arterial vasodilator; its hypotension results from reduced aldosterone synthesis via CYP11B2 inhibition, and the hypokalemia reflects that aldosterone deficiency rather than a reflex aldosterone surge.
13. A 60-year-old woman with adrenocortical carcinoma is started on mitotane. She is also taking warfarin and requires physiologic glucocorticoid replacement. Which of the following best predicts the effect of mitotane on these co-administered medications and the appropriate management?
A) Mitotane inhibits CYP3A4 and CYP2C9, so warfarin and glucocorticoid concentrations will rise; warfarin and steroid replacement doses should be reduced to avoid over-anticoagulation and glucocorticoid excess.
B) Mitotane is a potent inducer of CYP3A4 and CYP2B6 and also induces CYP2C9, accelerating the metabolism of warfarin and corticosteroids; warfarin doses commonly must be increased substantially with frequent INR monitoring, and glucocorticoid replacement doses must be increased (often doubled or tripled) to maintain adequate levels.
C) Mitotane has no clinically significant effect on warfarin or corticosteroid metabolism, so no dose adjustment of either medication is anticipated during therapy.
D) Mitotane displaces warfarin and corticosteroids from adipose tissue stores due to its lipophilicity, transiently increasing their plasma concentrations and requiring temporary dose reductions.
E) Mitotane selectively induces only CYP2C9, increasing warfarin clearance and necessitating a higher warfarin dose, but it has no effect on corticosteroid metabolism, so glucocorticoid replacement doses remain unchanged.
ANSWER: B
Rationale:
Mitotane is a potent inducer of multiple cytochrome P450 enzymes, most importantly CYP3A4 and CYP2B6, and it also induces CYP2C9. This broad enzyme induction accelerates the metabolism of many co-administered drugs. Warfarin clearance increases (the active S-enantiomer is a CYP2C9 substrate and the R-enantiomer a CYP3A4 substrate), so warfarin doses commonly must be increased substantially — often 50% or more — with frequent INR monitoring (every 2 weeks) until a new stable dose is reached; this is especially important because cortisol excess already predisposes to hypercoagulability. Corticosteroid metabolism is similarly accelerated, so glucocorticoid replacement doses must be increased (often doubled or tripled) to maintain adequate physiologic levels — particularly relevant in mitotane-treated patients who require replacement because of adrenal destruction.
Option A: Option A is incorrect because mitotane induces rather than inhibits these enzymes; induction lowers warfarin and corticosteroid concentrations, requiring dose increases, not reductions.
Option C: Option C is incorrect because mitotane has major, clinically significant effects on warfarin and corticosteroid metabolism through potent enzyme induction; the assumption of no interaction is unsafe and could lead to thromboembolism and inadequate glucocorticoid replacement.
Option D: Option D is incorrect because mitotane's lipophilicity drives its own tissue accumulation and slow kinetics but does not displace warfarin or corticosteroids from adipose stores to raise their levels; the dominant interaction is enzyme induction lowering their concentrations.
Option E: Option E is incorrect because mitotane induces CYP3A4 and CYP2B6 in addition to CYP2C9 and does accelerate corticosteroid metabolism; glucocorticoid replacement doses must be increased, not left unchanged.
14. A 58-year-old woman with Cushing syndrome and refractory hyperglycemia is being treated with mifepristone. Her clinician needs to determine whether the therapy is working. Which of the following is the most appropriate approach to monitoring mifepristone efficacy, and why?
A) Follow serial 24-hour urinary free cortisol (UFC), aiming for normalization, because mifepristone lowers cortisol production and a falling UFC is the most reliable indicator of therapeutic response.
B) Follow serum ACTH levels, aiming for suppression, because effective mifepristone therapy restores hypothalamic-pituitary negative feedback and reduces ACTH secretion from the corticotroph.
C) Follow late-night salivary cortisol, aiming for normalization, because mifepristone reduces nocturnal cortisol secretion and salivary cortisol is the most sensitive biochemical efficacy marker for this drug.
D) Follow serum cortisol, expecting it to fall below the normal range, because mifepristone produces a measurable decrease in circulating cortisol that parallels its clinical benefit.
E) Follow clinical and metabolic endpoints — glucose control and HbA1c, blood pressure, body weight, and resolution of cushingoid features — because mifepristone is a glucocorticoid receptor (GR) antagonist that does not lower cortisol secretion; cortisol and ACTH actually rise during therapy due to loss of negative feedback, rendering these biochemical markers uninterpretable as efficacy endpoints.
ANSWER: E
Rationale:
Mifepristone is a glucocorticoid receptor (GR) antagonist that blocks cortisol signaling at target tissues without reducing cortisol secretion. Because GR blockade removes cortisol's negative feedback on the hypothalamus and pituitary, ACTH and cortisol levels rise during therapy — an expected pharmacodynamic consequence rather than a sign of treatment failure. As a result, serum cortisol, UFC, late-night salivary cortisol, and ACTH cannot be used to judge mifepristone efficacy or to detect adrenal insufficiency. Treatment adequacy is instead assessed using clinical and metabolic endpoints: glucose control and HbA1c (mifepristone is specifically indicated for hyperglycemia in Cushing syndrome), blood pressure, body weight, and resolution of cushingoid features.
Option A: Option A is incorrect because mifepristone does not lower cortisol production, so UFC does not fall and would in fact tend to rise; UFC is not a valid efficacy marker for this drug.
Option B: Option B is incorrect because mifepristone does not restore negative feedback or suppress ACTH; on the contrary, ACTH rises because GR blockade prevents cortisol from suppressing pituitary ACTH release.
Option C: Option C is incorrect because mifepristone does not reduce cortisol secretion, so late-night salivary cortisol does not normalize and is not a valid efficacy endpoint; cortisol-based markers are uninterpretable on this drug.
Option D: Option D is incorrect because serum cortisol rises rather than falls during mifepristone therapy due to loss of negative feedback, so expecting cortisol to fall below normal misrepresents the drug's pharmacology and would mislead efficacy assessment.
15. A 47-year-old woman who underwent bilateral adrenalectomy for refractory Cushing disease 4 years ago presents with progressive skin hyperpigmentation, new headaches, and a markedly elevated adrenocorticotropic hormone (ACTH) level. MRI shows an enlarging invasive pituitary mass. Which of the following best identifies this condition and the mechanism driving it?
A) This is recurrent Cushing syndrome from an ectopic ACTH-secreting tumor that developed after adrenalectomy; the hyperpigmentation results from cortisol-driven melanocyte stimulation despite the absence of adrenal glands.
B) This is a non-functioning pituitary macroadenoma incidentally enlarging after adrenalectomy; the elevated ACTH is an unrelated laboratory artifact, and the hyperpigmentation reflects postoperative adrenal insufficiency from inadequate replacement.
C) This is pituitary apoplexy of a pre-existing adenoma triggered by the hemodynamic stress of adrenalectomy; the high ACTH and hyperpigmentation result from acute infarction releasing stored hormone.
D) This is Nelson syndrome: after bilateral adrenalectomy, cortisol production ceases and hypothalamic-pituitary negative feedback is permanently lost, driving unopposed ACTH hypersecretion and accelerated growth of the residual corticotroph adenoma; the very high ACTH and characteristic hyperpigmentation (from ACTH-driven melanocyte-stimulating activity) are clinical hallmarks.
E) This is a prolactinoma that developed after adrenalectomy due to loss of cortisol-mediated suppression of lactotrophs; the elevated ACTH is a cross-reacting assay finding, and dopamine agonist therapy is the definitive treatment.
ANSWER: D
Rationale:
This presentation is Nelson syndrome — the development of an aggressive, invasive ACTH-secreting corticotroph adenoma following bilateral adrenalectomy performed for refractory Cushing disease. After both adrenal glands are removed, cortisol production ceases entirely and the normal hypothalamic-pituitary negative feedback that restrains ACTH release and limits corticotroph tumor growth is permanently lost. The residual corticotroph adenoma then undergoes unopposed, sustained ACTH hypersecretion and accelerated, often invasive growth, producing mass effects such as headache and visual compromise. ACTH levels are characteristically very high (often above 500 pg/mL). The striking hyperpigmentation is a clinical hallmark, driven by ACTH's shared precursor and structural homology with melanocyte-stimulating hormone, which activates cutaneous melanocortin receptors. Management options include transsphenoidal surgery, radiotherapy, and medical therapy such as pasireotide and cabergoline.
Option A: Option A is incorrect because the hyperpigmentation and high ACTH arise from the residual corticotroph adenoma driven by lost feedback, not from an ectopic ACTH tumor; moreover, the patient has no adrenal glands to produce the cortisol that the option incorrectly invokes to explain melanocyte stimulation.
Option B: Option B is incorrect because the elevated ACTH is not a laboratory artifact and the mass is a functioning corticotroph adenoma; the hyperpigmentation reflects ACTH excess, not simply inadequate steroid replacement.
Option C: Option C is incorrect because the clinical picture is progressive tumor growth with sustained ACTH hypersecretion over years, not acute pituitary apoplexy from infarction, which would present abruptly rather than as gradual enlargement and progressive hyperpigmentation.
Option E: Option E is incorrect because the lesion is a corticotroph (ACTH-secreting) adenoma, not a prolactinoma; the high ACTH is genuine and central to the diagnosis, and dopamine agonist therapy is not the definitive treatment for Nelson syndrome, though cabergoline may be used adjunctively.
16. A 44-year-old woman with persistent Cushing disease after surgery is to begin cabergoline as adjunctive therapy. Her endocrinologist plans to use a dose of 3 mg per week and notes that this exceeds the dose she would use for a prolactinoma. Which of the following correctly relates the cabergoline dosing in Cushing disease to the appropriate cardiac surveillance?
A) Cabergoline doses for Cushing disease are higher than those for prolactinoma — often in the range of 1 to 7 mg per week versus 0.5 to 2 mg per week — because corticotroph adenomas have lower and more variable D2 receptor (D2R) expression than lactotroph adenomas; the higher cumulative exposure increases the relevance of cabergoline's valvulopathy risk, so baseline echocardiography is recommended before starting doses above 2 mg per week for this indication.
B) Cabergoline doses for Cushing disease are lower than those for prolactinoma because corticotroph adenomas are more sensitive to dopaminergic suppression; the low doses eliminate any need for cardiac surveillance.
C) Cabergoline doses are identical for both indications, and cardiac surveillance is unnecessary in Cushing disease because valvulopathy occurs only with daily Parkinson disease dosing.
D) Cabergoline doses for Cushing disease are higher than for prolactinoma, but the relevant surveillance is serial electrocardiography for QT prolongation rather than echocardiography, because cabergoline's dose-dependent cardiac toxicity is electrophysiologic.
E) Cabergoline doses for Cushing disease are higher than for prolactinoma, and the relevant surveillance is periodic pulmonary function testing, because the principal dose-dependent cardiopulmonary toxicity at these doses is pleuropulmonary fibrosis rather than valvulopathy.
ANSWER: A
Rationale:
The cabergoline dose required for Cushing disease is substantially higher than the dose used for prolactinoma. Most prolactinomas respond at 0.5 to 2 mg per week, whereas Cushing disease typically requires 1 to 7 mg per week. This reflects the lower and more variable D2R expression of corticotroph adenomas compared with lactotroph adenomas, which necessitates higher receptor occupancy to achieve adequate ACTH suppression. The higher weekly doses produce greater cumulative cabergoline exposure, which is the principal driver of cardiac valvulopathy risk — mediated by 5-HT2B receptor activation on valve fibroblasts. Accordingly, baseline echocardiography is recommended before starting cabergoline above 2 mg per week for this indication, with periodic surveillance during treatment. A planned dose of 3 mg per week crosses that threshold and warrants a baseline echocardiogram.
Option B: Option B is incorrect because corticotroph adenomas are less, not more, sensitive to dopaminergic suppression than lactotroph adenomas, so higher doses are required; and the higher cumulative exposure increases rather than eliminates the need for cardiac surveillance.
Option C: Option C is incorrect because cabergoline doses are not identical between the two indications, and valvulopathy risk is not confined exclusively to Parkinson disease dosing; surveillance is recommended above 2 mg per week in Cushing disease.
Option D: Option D is incorrect because cabergoline's principal dose-dependent cardiac toxicity is valvular (5-HT2B-mediated fibrosis) requiring echocardiography, not QT prolongation requiring serial electrocardiography; QT monitoring is relevant to steroidogenesis inhibitors such as ketoconazole and osilodrostat.
Option E: Option E is incorrect because although pleuropulmonary and retroperitoneal fibrosis are rare complications of long-term high-dose ergot dopamine agonist use, the principal dose-dependent surveillance concern at these doses is cardiac valvulopathy assessed by echocardiography, not pulmonary fibrosis assessed by pulmonary function testing.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.